Recombinant Human BTLA (C-mFc)

Recombinant Human BTLA (C-mFc) (CW47)

 

产品说明(Description)

Recombinant Human B- and T-Lymphocyte Attenuator is produced by our Mammalian expression system and the target gene encoding Lys31-Leu150 is expressed with a mFc tag at the C-terminus.

Accession #: Q7Z6A9-2

Known as: B- and T-Lymphocyte Attenuator; B- and T-Lymphocyte-Associated Protein; CD272; BTLA

 

制剂（Formulation）

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

 

质量控制（Quality Control） 

Purity:            Greater than 95% as determined by reducing SDS-PAGE.  

Endotoxin:    Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.

 

保存（Storage）

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.

Reconstituted protein solution can be stored at 4-7°C for 2-7 days.

Aliquots of reconstituted samples are stable at < -20°C for 3 months. 

 

背景（Background）

B- and T-Lymphocyte Attenuator (BTLA) is a single-pass type I membrane protein containing 1 Ig-like V-type (immunoglobulin-like) domain. BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a lymphocyte inhibitory receptor that inhibits lymphocytes during immune response. BTLA also is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.

 

电泳(SDS-PAGE)

 

FOR RESEARCH USE ONLY.